Verisante Technology, Inc. Exhibits at the 22nd Congress of the
European Academy of Dermatology in Istanbul, Turkey
Verisante Technology, Inc. Exhibits at the 22nd Congress of the
European Academy of Dermatology in Istanbul, Turkey
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sep 30, 2013) -
Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF)
(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer
detection technology, announced today that the Company is
exhibiting at the 22nd Congress of the European Academy
of Dermatology and Venereology ("EADV") in Istanbul, Turkey, from
October 3-6, 2013. Over 8,000 participants are expected at the
EADV's 22nd Annual Congress.
The Company will be demonstrating Aura?, an innovative device
for the detection of all major forms of skin cancer and
precancerous lesions, in support of sales and marketing efforts in
Europe. Interested parties are invited to view Aura? at our Exhibit
Booth #31.
The European medical device market is the second largest in the
world, worth over $78 billion and representing 30 per cent of the
world market - second only to the United States. Last year, Aura?
received the Conformite Europeenne (CE) Mark approval. CE Mark is
recognized by all the 27 Member States of the EU.
Verisante Aura? is indicated for use for the evaluation of skin
lesions that may be clinically suspicious for melanoma, squamous
cell carcinoma, basal cell carcinoma, and/or actinic keratosis when
a medical professional chooses to obtain additional information to
rule out one of the above conditions before making a final decision
to biopsy. Aura? is a non-invasive optical system that uses Raman
spectroscopy to biochemically analyze the skin, providing immediate
results. The device will help to automate the current process of
diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on
at-risk individuals, improving patient outcomes and
comfort.
About the
European Academy of Dermatology and Venereology
The EADV is a non-profit association, founded in 1987, whose
mission is to advance excellence in clinical care, research,
education and training in the field of dermatology and Venereology
and to act as the advocate and educator of patients particularly
those with cutaneous or venereal diseases.
The EADV organizes annually one main congress in one of the
European capitals and one spring meeting, offers training,
fostering courses and online teaching for continuing medical
education.
About Verisante
Technology, Inc.
Verisante is a medical device company committed to
commercializing innovative systems for the early detection of
cancer. The Verisante Aura? for skin cancer detection and the
Verisante Core? series for lung, colon and cervical cancer
detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device.
The cancer detection platform was developed by the BC Cancer Agency
and tested and refined at the Skin Care Centre at Vancouver General
Hospital. This exclusive platform technology allows Verisante to
develop and offer a range of compact, non-invasive cancer detection
devices that offer physicians immediate results for many of the
most common cancers. Aura? has been approved for sale in Canada,
Europe and Australia. Core? has not yet been approved for sale.
Verisante Aura? was awarded Popular Science Magazine's
"Best of What's New Award" for 2011, awarded a 2013 Prism Award for
Innovation in Photonics and an Edison Award for Excellence in
Innovation in 2013. Verisante Core? was named one of the top 10
cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor
disapproved of the contents of this press release. Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward Looking Statements
This release contains forward-looking statements, including, but
not limited to, statements regarding the future commercialization
of medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks,
and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These
statements are made based upon current expectations and actual
results may differ from those projected due to a number of risks
and uncertainties.